MRTX-500 Phase 2 Trial: Sitravatinib With Nivolumab in Patients With Nonsquamous NSCLC Progressing On or After Checkpoint Inhibitor Therapy or Chemotherapy - Concepedia

Concepedia

Publication | Open Access

MRTX-500 Phase 2 Trial: Sitravatinib With Nivolumab in Patients With Nonsquamous NSCLC Progressing On or After Checkpoint Inhibitor Therapy or Chemotherapy

DOI Full Paper Access

36

Citations

28

References

2023

Year

Kai He, David Berz, Shirish M. Gadgeel, Wade T. Iams, Débora S. Bruno, Collin M. Blakely, Alexander I. Spira, Manish R. Patel, David Waterhouse, Donald Richards,

Journal of Thoracic Oncology

Abstract

Sitravatinib with nivolumab had a manageable safety profile. Although ORR was not met, this combination exhibited antitumor activity and encouraged survival in CPI-experienced patients with nonsquamous NSCLC.

References

	Year	Citations

Page 1